Orlistat - Generic Drug Details

What are the generic sources for orlistat and what is the scope of freedom to operate?

Orlistat is the generic ingredient in two branded drugs marketed by Haleon Us Holdings and Cheplapharm, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

There are twelve drug master file entries for orlistat. Three suppliers are listed for this compound.

Summary for orlistat

US Patents:	0
Tradenames:	2
Applicants:	2
NDAs:	2
Drug Master File Entries:	12
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	103
Clinical Trials:	74
Drug Prices:	Drug price trends for orlistat
What excipients (inactive ingredients) are in orlistat?	orlistat excipients list
DailyMed Link:	orlistat at DailyMed

See drug prices for orlistat

Recent Clinical Trials for orlistat

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The Cleveland Clinic	PHASE4
Hubei Cancer Hospital	PHASE2
Ping Peng	PHASE2

See all orlistat clinical trials

Pharmacology for orlistat

Drug Class	Intestinal Lipase Inhibitor
Mechanism of Action	Lipase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for orlistat

A08AB	Peripherally acting antiobesity products
A08A	ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS
A08	ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS
A	Alimentary tract and metabolism

Paragraph IV (Patent) Challenges for ORLISTAT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ALLI	Capsules	orlistat	60 mg	021887	1	2010-09-08

US Patents and Regulatory Information for orlistat

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cheplapharm	XENICAL	orlistat	CAPSULE;ORAL	020766-001	Apr 23, 1999		RX	Yes	Yes
Haleon Us Holdings	ALLI	orlistat	CAPSULE;ORAL	021887-001	Feb 7, 2007		OTC	Yes	Yes

Expired US Patents for orlistat

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Haleon Us Holdings	ALLI	orlistat	CAPSULE;ORAL	021887-001	Feb 7, 2007
Cheplapharm	XENICAL	orlistat	CAPSULE;ORAL	020766-001	Apr 23, 1999
Cheplapharm	XENICAL	orlistat	CAPSULE;ORAL	020766-001	Apr 23, 1999
Haleon Us Holdings	ALLI	orlistat	CAPSULE;ORAL	021887-001	Feb 7, 2007

EU/EMA Drug Approvals for orlistat

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
GlaxoSmithKline (Ireland) Limited	Alli (previously Orlistat GSK)	orlistat	EMEA/H/C/000854Alli is indicated for weight loss in adults who are overweight (body mass index, BMI, ≥ 28 kg/m2) and should be taken in conjunction with a mildly hypocaloric, lower-fat diet.	Authorised	no	no	no	2007-07-22
CHEPLAPHARM Arzneimittel GmbH	Xenical	orlistat	EMEA/H/C/000154Xenical is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (BMI) greater or equal to 30 kg/m2, or overweight patients (BMI > 28 kg/m2) with associated risk factors.Treatment with orlistat should be discontinued after 12 weeks if patients have been unable to lose at least 5% of the body weight as measured at the start of therapy.	Authorised	no	no	no	1998-07-29

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: Orlistat

Last updated: July 28, 2025

Introduction

Orlistat, a lipase inhibitor primarily used for weight management and obesity treatment, remains a significant component of the pharmaceutical landscape due to the escalating global obesity epidemic. Since its commercial debut, Orlistat’s market performance has been characterized by evolving regulatory, competitive, and consumer trends. This comprehensive analysis explores the market dynamics and financial trajectory shaping Orlistat’s future prospects.

Pharmaceutical Profile and Therapeutic Context

Orlistat operates by inhibiting gastric and pancreatic lipases, reducing dietary fat absorption by approximately 30%. Approved by the U.S. Food and Drug Administration (FDA) in 1999 as a prescription (Xenical) and reclassified later for over-the-counter (OTC, Alli) use, it is marketed globally across multiple regions. The drug targets overweight and obese populations, aiming to mitigate comorbidities such as type 2 diabetes and cardiovascular diseases, thereby addressing a large and increasing health concern worldwide.

Market Drivers

1. Rising Global Obesity Rates

Obesity prevalence continues to surge, driven by sedentary lifestyles, high-calorie diets, and urbanization. The World Health Organization (WHO) estimates that over 650 million adults were obese as of 2016, with numbers projected to increase further. This creates an expanding market segment seeking effective weight management pharmacotherapy [1].

2. Expanding Aging Population

Older adults face higher obesity-related health risks, fueling demand for safe, efficacious weight loss solutions. Governments are prioritizing obesity management as part of broader public health initiatives, influencing market growth trajectories.

3. Regulatory Environment Favoring OTC Products

The conversion of Orlistat to OTC status in several markets, notably the U.S., has widened accessibility and boosted sales volumes. The OTC shift reduces barriers to entry, encouraging consumer autonomy and increasing market penetration.

4. Increasing Awareness and Lifestyle Management

Enhanced awareness of obesity's health risks and more aggressive marketing campaigns have driven consumer interest. Healthcare providers are increasingly adopting pharmacological interventions as part of comprehensive weight management plans.

Market Restraints

1. Adverse Effects and Safety Concerns

Common side effects—steatorrhea, flatulence, oily stools—affect patient adherence. Serious adverse events, though rare, including hepatotoxicity, have prompted regulatory scrutiny and cautionary advisories, potentially restraining market expansion [2].

2. Availability of Alternative Therapies

Emergence of newer weight management drugs with better efficacy and tolerability profiles, such as GLP-1 receptor agonists (e.g., liraglutide, semaglutide), threaten Orlistat’s market share.

3. Limited Efficacy as a Monotherapy

Orlistat's modest weight loss (average of 5-10% of body weight) often insufficient for significant health benefits, leading clinicians to prescribe multimodal interventions. This may limit its standalone market potential.

4. Regulatory Challenges in Developing Markets

Stringent regulation and lack of approval in certain regions (e.g., Russia, China) restrict market access, reducing potential revenues.

Market Segmentation and Revenue Streams

The Orlistat market is segmented as follows:

• Prescription (RX) Segment: Historically dominant, comprising higher-dose formulations marketed through physicians. Revenue contribution is robust in regions with strong healthcare infrastructure.

• Over-the-Counter (OTC) Segment: Gained prominence post-2007 FDA approval of Alli. OTC sales are driven by consumer self-medication, largely supported by retail pharmacy chains and online channels.

The global market value for Orlistat was estimated at approximately USD 300 million in 2022, with a compound annual growth rate (CAGR) of around 4% projected through 2028 [3].

Geographical Market Dynamics

• North America: Leading region with mature OTC markets, high awareness, and extensive healthcare infrastructure. The U.S. contributes the majority of revenues, benefitting from the OTC status.

• Europe: Growing market driven by obesity prevalence and regulatory acceptance, especially in the UK, Germany, and France.

• Asia-Pacific: Rapidly expanding due to urbanization, increasing obesity rates, and improving healthcare access. Countries like India, China, and Australia offer substantial growth opportunities.

Competitive Landscape

The market for obesity pharmacotherapy is increasingly competitive, with Orlistat facing competition from emerging therapies:

• Newer Oral Agents: Phentermine-topiramate, lorcaserin (withdrawn in some regions), and naltrexone-bupropion combinations.

• Injectable Therapies: GLP-1 receptor agonists such as semaglutide and liraglutide exhibit superior efficacy, posing a significant challenge to Orlistat.

• Lifestyle and Surgical Interventions: Bariatric surgery and lifestyle modifications continue to interplay with pharmacological treatments, influencing overall market dynamics.

Financial Trajectory and Future Outlook

Orlistat’s revenue growth is projected to stabilize, with incremental gains driven by emerging markets and expanded OTC usage. Patent expirations for the original formulations have led to generic variety, intensifying price competition and pressuring profit margins. Key factors influencing future financial performance include:

• Patent and Formulation Developments: Patent cliffs in mature regions are prompting generic entries, reducing prices but also potentially expanding access.

• Product Innovation: While current formulations lack significant innovation, ongoing research may lead to improved delivery methods or combination therapies that incorporate Orlistat’s mechanism.

• Regulatory Developments: Enhanced safety data or new approvals could revitalize market interest and expand indications.

Impact of COVID-19 Pandemic

The pandemic initially disrupted supply chains and healthcare delivery, curbing prescriptions. However, increased focus on health and wellness post-pandemic has rekindled interest in weight management solutions. The rise in telemedicine and OTC self-care options presents both challenges and opportunities for sales channels.

Regulatory and Patent Landscape

Global patent expirations have paved the way for generics, increasing accessibility but compressing revenues. Regulatory bodies have issued warnings regarding adverse effects, emphasizing the need for clear labeling and patient education, which directly impact market acceptance and financial outcomes.

Key Market Players

Major pharmaceutical companies involved in Orlistat’s distribution include GlaxoSmithKline, Roche, and generic manufacturers entering the space post-patent expiry. Strategic partnerships and licensing agreements influence market dynamics and pricing strategies.

Conclusion

Orlistat’s market trajectory is shaped by a confluence of rising obesity rates, regulatory shifts, technological advancements, and competitive pressures. While maturity and patent expirations challenge profitability, expanding OTC markets and Asia-Pacific growth avenues sustain its relevance. Innovation and safety profile improvements will be critical for maintaining competitive advantage and ensuring sustained financial performance.

---

Key Takeaways

• The global obesity crisis underscores ongoing demand for weight management medications like Orlistat.
• Regulatory shifts, particularly the OTC availability of Alli, have expanded the market and increased consumer access.
• Market growth faces constraints from side effects, competition from newer therapies, and patent expirations.
• Emerging markets and regional regulatory environments offer growth opportunities, especially in Asia-Pacific.
• Sustained profitability hinges on product innovation, patient education, and strategic positioning amid intense competition.

---

FAQs

1. What is the current market size and outlook for Orlistat?
The global market was valued at approximately USD 300 million in 2022 with a projected CAGR of around 4% through 2028, driven by increasing obesity prevalence and OTC expansion.

2. How does Orlistat compare with newer weight-loss drugs?
While Orlistat offers moderate weight loss with a well-established safety profile, newer agents like semaglutide show superior efficacy but often come with higher costs and different safety considerations.

3. What are the main regulatory challenges for Orlistat?
Safety concerns about adverse effects and hepatotoxicity have led to regulatory warnings. Patent expiries and generic competition also influence market dynamics.

4. Which regions offer the most growth opportunities for Orlistat?
Asia-Pacific presents rapid growth due to rising obesity rates and improving healthcare access, while North America remains the largest market with high OTC sales.

5. What strategies can pharmaceutical companies adopt to sustain Orlistat’s market presence?
Focused on product innovation, enhancing safety profiles, expanding access through OTC channels, and forming strategic partnerships in emerging markets.

---

References

[1] WHO Obesity and Overweight Factsheet, 2021
[2] FDA Drug Safety Communication, 2010
[3] Market Research Future, 2022 Report on Obesity Pharmacotherapy